Weekend Edition: When Did Big Alcohol Start Defending Weed?
The Alcohol Industry Just Switched Sides
Wine and spirits wholesalers are now lobbying to keep THC drinks legal, a congressman’s “White House backing” turns out to be shaky, and cannabis is quietly becoming part of cancer care.
Here’s the quiet truth about this week: the big fights in cannabis aren’t about legalization anymore. That argument ended years ago and everybody knows it. The action has moved somewhere less glamorous but honestly more decisive, into hemp rules, hospital policies, banking, insurance, and taxes.
Every one of those boring-sounding decisions is really the same question in disguise. Does cannabis grow up into a mature industry, or does it stay stuck in this weird limbo between legal and not? And while the politicians haggle over administrative details, the research keeps quietly stacking up in cannabis’s favor. The public moved a long time ago. Now it’s the systems, the banks, the insurers, the hospitals, that have to catch up. Let me walk you through the week.
That congressman’s “White House support” for the hemp bill looks a lot shakier up close.
Reps. Andy Barr and Angie Craig introduced a bipartisan bill to save much of the hemp industry before the November restrictions hit, and Barr’s office said it’s “backed by the White House.” Sounds great. One problem: the administration isn’t actually confirming that.
According to Marijuana Moment, White House sources want to fix the coming hemp ban but have real concerns about the provisions allowing inhalable hemp products. So the picture is murkier than the press release suggests, and that gap between “the White House backs my bill” and “the White House backs part of the problem my bill addresses” matters enormously right now.
Here’s why. If Congress doesn’t modify the November restrictions, thousands of hemp-derived THC products could vanish from shelves nationwide. And as I keep pointing out, the damage doesn’t wait for the deadline. Farmers are already rethinking what to plant, manufacturers are delaying production, and retailers are trimming inventory, all because nobody knows what stays legal. Markets can adapt to bad news. What they can’t stand is not knowing, and right now not knowing is the whole situation.
The bottom line: Hemp’s future hinges less on the science at this point and more on whether a bill with genuinely uncertain backing can get through Congress in time.
The alcohol industry just came out for keeping THC drinks legal, and that’s a bigger deal than it sounds.
The biggest surprise this week came from a direction almost nobody expected. The Wine & Spirits Wholesalers of America endorsed legislation to keep hemp THC beverages federally legal instead of letting them get banned in November. They do want lawmakers to revisit the proposed tax rate, but the endorsement itself is the story.
Think about how recently alcohol and cannabis were treated as mortal enemies fighting over the same customers. Now a major alcohol lobby is looking at THC beverages and seeing another beverage category to work with rather than an existential threat to crush. That’s a genuine shift, and part of it is simple self-interest, distributors would rather sell these drinks than fight them, but the effect on the politics is real either way.
And this is what changes momentum in Washington. When a well-funded, established industry like alcohol distribution starts lobbying on the same side as hemp, the opposition’s job gets a lot harder. It’s one thing to ban a scrappy young industry. It’s another when the wine and spirits guys are in the room arguing to keep the product legal.
The bottom line: Hemp beverages are quietly becoming part of mainstream beverage policy, not just cannabis policy, and having alcohol distributors as allies rewrites the political math.
Register HERE.
CBD is quietly becoming part of cancer care, whether or not doctors bring it up.
A new study found nearly 20% of cancer survivors have used CBD after their diagnosis, mostly for pain, anxiety, depression, sleep problems, and neuropathy. More than half said it gave them at least some relief.
Let me be careful here, because the researchers were, this does not mean CBD treats cancer itself. That’s not the claim, and I won’t stretch it into one. What it actually shows is something healthcare providers are increasingly having to reckon with: patients are already folding cannabinoids into their supportive care regardless of whether their physician ever mentions it.
That pattern is worth understanding, because medicine often changes from the bottom up. Patients adopt things that help them well before the formal healthcare system catches up and blesses it. CBD looks like it’s following exactly that path, moving from “alternative medicine” into ordinary symptom management one patient at a time. For anyone in this space, the signal is that the cannabinoid conversation in healthcare isn’t coming someday. It’s already happening in exam rooms, just often without the doctor in the loop.
The bottom line: Cannabinoids are sliding into everyday symptom management rather than staying parked in the alternative-medicine corner, and patients are leading that shift.
The House expanded military psychedelic research to 2033, while cannabis amendments couldn’t even get a vote.
The House approved amendments extending Department of Defense psychedelic research through 2033 and codifying Trump’s executive order encouraging military study of psychedelic-assisted therapies. Meanwhile, separate amendments dealing with marijuana testing for military recruits didn’t even get votes.
That contrast is the thing to sit with. Psychedelic research keeps expanding smoothly inside federal institutions, while cannabis reform stays politically knotted up despite way broader public acceptance. It’s a little strange when you say it out loud, the more established, more normalized substance is the one that keeps stalling, while the newer, more exotic therapies sail through on a bipartisan basis.
Part of what’s happening is that psychedelics have wrapped themselves in the veteran and military-readiness framing, which is about the most politically bulletproof packaging any drug policy can have. And this matters beyond the military, because federal research funding tends to shape civilian healthcare policy down the line. Expanded military PTSD studies today can become the evidence base for treatments that reach everyone else later.
The bottom line: Washington keeps pouring money into psychedelic science while cannabis policy limps along unevenly, and the substance with less public support is somehow having an easier time.
The Senate is going after cannabis’s insurance problem, and this one flies under the radar.
A bipartisan Senate bill would stop federal regulators from punishing insurance companies just for insuring state-licensed cannabis businesses. Insurance almost never makes headlines, which is exactly why this is easy to miss and genuinely important.
Here’s the thing people forget: before a lender finances a project or a landlord signs a tenant, somebody wants to see insurance. It’s the invisible layer underneath basically every commercial real estate deal and expansion. When reliable coverage is hard to get because of federal status, everything downstream gets more expensive and more fragile.
I’ve been banging the drum that cannabis’s biggest obstacle isn’t legalization anymore, it’s financial infrastructure. Banking gets all the attention, but insurance is the quieter twin of that problem, and it touches nearly every transaction that lets a business grow. Fixing it wouldn’t generate a single exciting headline, and it would matter more than most of the ones that do.
The bottom line: Banking isn’t the only financial wall cannabis is hitting anymore. Insurance quietly sits under almost every deal, and it needs fixing too.
Kentucky is debating whether hospitals should let terminally ill patients use medical cannabis.
Kentucky lawmakers heard testimony on legislation that would let terminally ill patients use medical cannabis inside hospitals. The advocates’ argument is simple and hard to push back on: a patient shouldn’t lose access to medicine their doctor approved just because they got admitted to a hospital.
Hospitals have long banned cannabis because of federal law, which made sense as a liability-driven reflex. But medical rescheduling has cracked that door open again, and it exposes a strange contradiction in how we treat this stuff. A patient can have physician-approved medical cannabis at home, then walk into a healthcare facility, the one place supposedly organized entirely around their care, and suddenly be told no.
This is really cannabis’s next frontier, and it’s not legalization, it’s healthcare integration. Hospitals are one of medicine’s last big institutional holdouts, and for good reason they move cautiously. But you can’t really call something fully medical while the medical system itself won’t let people use it in a hospital bed. Kentucky poking at this, specifically for terminally ill patients, is exactly the kind of sympathetic, narrow case that tends to move these debates.
The bottom line: Medical cannabis isn’t fully medical until hospitals treat it like medicine, and Kentucky is testing that line in the hardest-to-argue-against way.
A federally funded study found cannabis may help people cut opioid use and ease withdrawal.
A federally funded study found that cannabis use during opioid withdrawal was associated with lower self-reported opioid consumption, with participants frequently saying they used marijuana to take the edge off withdrawal symptoms while reducing their intake.
I want to stay honest about the limits, because the researchers did. This does not prove cannabis replaces established addiction treatment, and nobody should read it that way. It’s a signal worth studying more, not a prescription.
But the reason it matters goes beyond the specific finding. Harm reduction is becoming a serious research priority, and cannabis is increasingly being studied as a potential tool in that toolkit rather than dismissed as a public-safety problem. That reframing is the real shift here. For decades cannabis got filed under “crime and enforcement.” Now federally funded researchers are looking at it as a possible piece of how we treat opioid dependence, which is a very different lens, and one that could reshape policy if the evidence keeps building.
The bottom line: Researchers are increasingly treating cannabis as part of healthcare, potentially another tool against opioid dependence rather than a replacement for real treatment, and definitely not just a law-enforcement issue.
California’s treasurer is holding a hearing on the banking mess, because cash-only still isn’t sustainable.
California Treasurer Fiona Ma announced a public hearing on the banking challenges facing cannabis businesses. Years into legalization, tons of operators still can’t get basic financial services because marijuana is federally illegal, and the hearing will dig into cash management, lending, payments, and access to capital.
This ties right back to the insurance story, because it’s the same underlying disease showing up in a different spot. The industry doesn’t just need permission to exist, it needs functioning financial plumbing, and right now it’s operating without a lot of it. Being forced into cash-heavy operations isn’t just inconvenient, it drives up costs, creates real safety risks, and puts legal operators at a permanent disadvantage against everybody with normal banking.
A multibillion-dollar industry running partly on cash is not a stable long-term setup, full stop. It’s the kind of thing that looks almost absurd in hindsight once it finally gets fixed, and hearings like this are how the fixing slowly starts. Not thrilling, but this is where the actual competitiveness of the industry gets decided.
The bottom line: Cash-only commerce just doesn’t work for an industry this size, and California putting a spotlight on it is a step toward the unglamorous fix cannabis actually needs.
Final thought
Cannabis has reached the stage where the biggest battles aren’t about legalization at all anymore. They’re about infrastructure. Insurance. Hospitals. Banking. Taxes. Research.
None of that stuff gets a crowd fired up the way a legalization campaign does. But it’s exactly the stuff that decides whether an industry actually survives. And history is pretty clear on this: markets rarely collapse because the customers vanished. They collapse because the institutions around them never caught up, because the banking, the insurance, the legal plumbing never got built to match the demand.
Cannabis already won the public. That fight is over, and cannabis won it convincingly. The next one is quieter and harder, winning over the systems that let a legitimate business just operate like any other business. The companies that come out on top in this next era won’t be the ones growing the best product. They’ll be the ones who understand government the best.
That’s what this newsletter is for.
What’s the biggest regulatory challenge your operation is facing right now? Hit reply, I read every response and it shapes what I cover next week.
If this was useful, forward it to someone in the cannabis space or hit the restack button on Substack. It’s how this community grows.